Legend Biotech (LEGN) Announces Preliminary Sales for CARVYKTI

Legend Biotech (NASDAQ: LEGN) disclosed:

Legend Biotech Announces Preliminary Sales for CARVYKTI® for the Quarter Ended June 30, 2025

Pursuant to the Collaboration and License Agreement dated as of December 21, 2017, as amended, between Legend Biotech USA Inc., Legend Biotech Ireland Limited, Janssen Biotech, Inc. and Janssen Pharmaceutica NV (together, “Janssen”), on July 16, 2025, Legend Biotech Corporation (“Legend Biotech”) announced that CARVYKTI® generated approximately $439 million in net trade sales during the quarter ended June 30, 2025. The net trade sales figure is based on information provided to Legend Biotech by Janssen, and Legend Biotech has not independently verified the accuracy of such sales figure.

The sales figure is based on information available to Legend Biotech as of the date of this Form 6-K, and the determination of the amount of any revenue or gross profit to be recorded in Legend Biotech’s consolidated statement of operations is subject to completion by management of Legend Biotech of its financial statements as of and for the period ended June 30, 2025. Legend Biotech’s independent registered public accountants have not audited, reviewed or performed any procedures with respect to this data and accordingly they have not expressed an opinion or provided any other form of assurance with respect thereto.

You May Also Be Interested In

• Boeing names Ryan Shedd as new SVP and controller
• Oruka Therapeutics (ORKA) files $1B mixed shelf
• Home Depot expands executive roles, grants $500K in restricted stock